stockrow
Saturday 7 November 2026
Export MTNB’s income statement to Excel — free account
Matinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.
- EPS
- +79.6%
- Free cash flow
- +9.15%
- Total debt
- −54.5%
Quarter to June 2026, against a year earlier
1.19
0.03
+2.59%
Follow MTNB
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 4 | 3 | 2 | 1 | — | — |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
— | 749.80 | 278.81 | 1,296.21 | 792.96 | 1,108.52 | 36.26 | 11.41 | — | — |
Altman Z-Score |
— | 8.61 | 2.79 | 23.84 | 19.95 | 11.01 | 2.26 | (7.44) | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | (13.46) | (7.89) | (0.79) | 7.38 | 1.52 | (5.66) | (22.34) | — | — |
P/Operating CF |
— | (58.60) | (22.30) | (67.31) | (62.20) | (53.67) | (26.89) | (10.68) | — | — |
P/B ratio |
— | 22.61 | 9.18 | 11.35 | 4.47 | 4.05 | 3.16 | 2.54 | — | — |
Price to Tangible BV |
— | 30.93 | 11.62 | 11.89 | 4.57 | 4.15 | 3.27 | 2.73 | — | — |
EV/Sales |
— | 700.41 | 219.44 | 1,186.27 | 618.97 | 849.28 | 27.23 | 8.20 | — | — |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | (9.15) | (4.45) | (21.42) | (12.04) | (10.69) | (4.53) | (2.30) | — | — |
EV/FCF |
— | (8.44) | (4.23) | (20.82) | (12.04) | (10.51) | (4.33) | (2.26) | — | — |
Quick Ratio |
2.95 | 4.22 | 4.42 | 9.05 | 16.49 | 11.42 | 6.72 | 5.27 | 2.75 | 2.77 |
Current Ratio |
3.16 | 4.50 | 4.61 | 9.66 | 17.25 | 11.73 | 8.06 | 5.93 | 3.01 | 2.79 |
Net Debt/EBITDA |
0.52 | 0.45 | 0.86 | 1.54 | 2.54 | 2.10 | 1.23 | 0.61 | 0.31 | 0.62 |
Debt/Assets |
0.17% | 0.47% | 0.54% | 0.14% | 0.03% | 0.00% | 0.05% | 0.07% | 0.09% | 0.07% |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.06 | 0.03 | 0.00 | 0.00 |
Operating CF/Net income |
0.51 | 0.35 | 0.69 | 0.77 | 0.75 | 0.64 | 0.91 | 0.67 | 0.66 | 0.64 |
Capex/Depreciation |
0.00 | (9.37) | (2.45) | (0.52) | (0.01) | (0.25) | (0.80) | (0.21) | 0.00 | 0.73 |
| (336.12%) | (1,089.33%) | (264.65%) | (103.29%) | (52.23%) | (42.12%) | (47.11%) | (82.11%) | (180.73%) | (176.54%) | |
| (131.62%) | (270.93%) | (87.22%) | (60.80%) | (41.80%) | (35.80%) | (39.56%) | (65.62%) | (128.50%) | (110.46%) | |
ROIC |
(177.63%) | (313.71%) | (247.23%) | (232.74%) | (306.30%) | (547.23%) | (195.88%) | (272.15%) | (5,735.31%) | (553.44%) |
Return on Tangible Assets |
(344.93%) | (422.89%) | (121.97%) | (64.03%) | (39.05%) | (49.14%) | (64.93%) | (154.55%) | (416.18%) | (398.65%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 6,019.04% | 5,665.69% | 12,510.69% | 9,070.69% | 44,190.91% | 523.15% | 1,321.99% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 5,104.61% | 6,660.10% | 8,659.58% | 6,320.91% | 30,863.64% | 348.18% | 946.44% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.14 | 0.09 | 0.07 | 0.03 | 0.02 | 0.02 | 0.03 | 0.05 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 2,403.14% | 3,199.58% | 3,324.39% | 2,883.64% | 16,642.42% | 173.12% | 451.46% | 0.00% | 0.00% |
Graham Net Nets |
— | 0.04 | 0.16 | 0.07 | 0.20 | 0.20 | 0.23 | 0.20 | — | — |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
— | (29.66%) | (25.59%) | (6.16%) | (8.82%) | (10.89%) | (20.63%) | (53.31%) | — | — |
Free Cash Flow Yield |
— | (11.07%) | (18.59%) | (4.40%) | (6.48%) | (7.29%) | (17.34%) | (31.77%) | — | — |
Revenue per Share |
0.00 | 1.24 | 0.92 | 0.46 | 0.60 | 0.12 | 11.02 | 3.78 | 0.00 | 0.00 |
Operating CF per Share |
(79.57) | (94.94) | (78.85) | (72.75) | (66.11) | (54.29) | (66.24) | (52.72) | (48.94) | (19.20) |
Capex per Share |
0.00 | (7.81) | (4.09) | (2.09) | (0.02) | (0.93) | (3.08) | (0.75) | 0.00 | 0.92 |
Free Cash Flow per Share |
(79.57) | (102.75) | (82.94) | (74.85) | (66.13) | (55.22) | (69.32) | (53.47) | (48.94) | (18.29) |
Cash per Share |
55.41 | 61.82 | 95.85 | 144.68 | 223.89 | 177.15 | 99.63 | 47.64 | 22.59 | 11.09 |
Shareholders Equity per Share |
92.98 | 88.50 | 123.31 | 170.63 | 242.60 | 187.21 | 126.68 | 66.41 | 23.38 | 13.23 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
92.98 | 88.50 | 123.31 | 170.63 | 242.60 | 187.21 | 126.68 | 66.41 | 23.38 | 13.23 |
Free Cash Flow |
(6.12) | (12.40) | (10.86) | (14.50) | (17.37) | (15.48) | (20.05) | (15.50) | (15.88) | (6.68) |
Working Capital |
3.12 | 6.19 | 10.25 | 26.83 | 57.99 | 46.65 | 30.25 | 12.92 | 5.36 | 2.61 |
Capital Expenditures |
— | (0.94) | (0.54) | (0.41) | (0.01) | (0.26) | (0.89) | (0.22) | — | 0.34 |
Net Current Asset Value |
1.90 | 4.22 | 9.28 | 22.73 | 54.32 | 42.16 | 26.35 | 9.69 | 2.97 | 1.70 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
— | 6.29 | 4.47 | 4.52 | 0.04 | 7.88 | 0.28 | 0.20 | — | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.15 | 0.06 | 0.11 | 0.45 | 0.67 | 0.67 | 0.53 | 0.55 | 2.04 | 3.30 |
Cash ROIC |
(53.54%) | (68.10%) | (37.70%) | (23.72%) | (14.17%) | (15.15%) | (30.62%) | (46.86%) | (106.35%) | (75.15%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Payables |
0.49 | 0.53 | 0.44 | 0.49 | 0.51 | 0.64 | 0.78 | 0.57 | 0.30 | 0.21 |
Average Assets |
9.11 | 12.12 | 17.18 | 30.09 | 55.60 | 66.15 | 53.07 | 34.96 | 18.87 | 9.92 |
Average Common Equity |
3.57 | 3.01 | 5.66 | 17.71 | 44.50 | 56.21 | 44.57 | 27.94 | 13.42 | 6.21 |
Columns are period end dates · fundamentals updated 2 Nov 2026